Quantoom Biosciences
A bankruptcy procedure is open for Quantoom Biosciences according to publications in the Belgian State Gazette. The 2023 annual accounts show negative equity (€-1.18M) and a net result of €-14.23M.
| Equity | €-1.18M |
| Net result | €-14.23M |
| Staff (FTE) | 69.1 |
| Better than sector | 25% |
Fragile profile, watch health in particular.
All 5 axes are computed from data Checked has read.
Bankruptcy opened
A bankruptcy procedure is already open, a probability score is no longer meaningful. See the insolvency timeline for the state of the procedure.
Unlock the full score breakdown, per-year score history and the indicative credit limit from Kantoor S.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | -2.1% | 28.3% | |
| Net result | €-14.23M | €-22k | |
| Equity | €-1.18M | €71k | |
| Total assets | €57.27M | €432k |
| Fiscal year | 2023 |
|---|---|
| Deposit | volledig |
| Revenue | €8.27M |
| EBITDA | €-9.44M |
| Net profit | €-14.23M |
| Cash flow | €-9.23M |
| Staff costs | €6.95M |
| Income taxes | - |
| Dividends | - |
| Total assets | €57.27M |
| Equity | €-1.18M |
| Debt | €58.39M |
| of which ≤ 1y | €12.09M |
| of which > 1y | €38k |
| Working capital | €27.37M |
| Employees (FTE) | 69.1 |
| 2023 | |
|---|---|
| Current ratio | 3.26 |
| Quick ratio | 3.08 |
| Working capital ratio | 47.8% |
| Solvency | -2.1% |
| Debt / equity | -49.62 |
| Long-term debt ratio | -0.03 |
| Interest coverage | -21.32 |
| Gross margin | 3.2% |
| Net margin | -172.0% |
| ROA | -24.8% |
| ROE | 1209.5% |
| EBITDA margin | -114.1% |
| Days sales outstanding | 233d |
| Days payable outstanding | 449d |
| Inventory turnover | 3.62 |
| Days inventory (DSI) | 101d |
| Line item | Code | 2023 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €57.27M |
| Fixed assets | 21/28 | €17.81M |
| Intangible fixed assets | 21 | €15.75M |
| Tangible fixed assets | 22/27 | €1.81M |
| Financial fixed assets | 28 | €239k |
| Current assets | 29/58 | €39.46M |
| Stocks & contracts in progress | 3 | €2.21M |
| Amounts receivable within one year | 40/41 | €26.11M |
| Cash & bank | 54/58 | €11.06M |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €57.27M |
| Equity | 10/15 | €-1.18M |
| Contributions / capital | 10/11 | €866k |
| Accumulated profits (losses) | 14 | €-8.37M |
| Provisions & deferred taxes | 16 | €55k |
| Amounts payable | 17/49 | €58.39M |
| Amounts payable after one year | 17 | €38k |
| Amounts payable within one year | 42/48 | €12.09M |
| Trade debts payable within one year | 44 | €9.85M |
| Income statement | ||
| Turnover | 70 | €8.27M |
| Operating result | 9901 | €-14.45M |
| Financial income | 75 | €1.24M |
| Financial charges | 65 | €1.02M |
| Result before taxes | 9903 | €-14.23M |
| Net result for the period | 9904 | €-14.23M |
| Result to be appropriated | 9905 | €-14.23M |
-
Alerion BVLegal entityDirectorState Gazette act 24366758 (26-02-2024)Current26-02-2024 → present
-
Viva Finance SRLLegal entityDirectorState Gazette act 24366758 (26-02-2024)Current26-02-2024 → present
-
Deloitte Réviseur d'EntreprisesAuditorState Gazette act 23120809 (20-09-2023)Current20-09-2023 → present
-
ANTROBUSDirectorState Gazette act 21101798 (24-08-2021)Current24-08-2021 → present
-
Jean-Paul PrieelsBoard memberState Gazette act 21037391 (24-03-2021)Current24-03-2021 → present
-
José CastilloManaging directorState Gazette act 20102637 (04-09-2020)Current04-09-2020 → present
-
Kabeer AzizDirectorState Gazette act 20102637 (04-09-2020)Current04-09-2020 → present
2 events
- 26-02-2024 Resigned· Director
- 04-09-2020 Appointed· Director
Former directors (3)
-
Jean PrieelsDirectorState Gazette act 24366758 (26-02-2024)Former- → 26-02-2024
-
Pierre MorgonDirectorState Gazette act 20102637 (04-09-2020)Former04-09-2020 → 26-02-2024
2 events
- 26-02-2024 Resigned· Director
- 04-09-2020 Appointed· Director
-
Hugues BultotManaging directorState Gazette act 20102637 (04-09-2020)Former- → 04-09-2020
| Role | Name | Tenure | Source |
|---|---|---|---|
| Curator | ISABELLE BRONKAERT CHAUSSEE DE THUIN 164,
6032 MONT-SUR-MARCHIENNE |
20-10-2025 → present | Belgian State Gazette |
| Curator | KARL DE RIDDER RUE DU PARC,49, 6000 CHARLEROI-
.
Date provisoire de cessation de paiement : 20/10/2025 |
20-10-2025 → present | Belgian State Gazette |
| NACE primary | Vervaardiging van geneesmiddelen(21201) |
| Legal form | Public limited company(014) |
| Incorporation | 02-03-2020 |
| Status | Active |
| Postal code | 1400 |
| First BS signal | 27-10-2025 |
| Latest BS signal | 27-10-2025 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 52034B1039/00Z004 | Wallonia | 9,994 m² | 1 · 3,265 m² | 11.1 m · 3 fl. |
| 21332B0081/00H002 | Brussels | 3,929 m² | 1 · 1,150 m² | 30.4 m · 9 fl. |
| 25099D0025/00L003 | Wallonia | 3,517 m² | 1 · 1,386 m² | 7.0 m · 2 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
28-01-2025 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "Quantoom Biosciences"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}21-11-2024 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": "proposal",
"notary": {
"name": "Indekeu - de Crayencour",
"firm_city": null,
"firm_name": null,
"office_city": "Bruxelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2024-11-21",
"filing_date": "2024-11-06",
"act_kind_objet": "D\u00E9p\u00F4t d\u0027un projet commun d\u0027op\u00E9ration assimil\u00E9e \u00E0 une scission partielle"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2024-12-20",
"unanimous": true
},
"conversion": null,
"detected_kind": "demerger_partial",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0744.643.858",
"name": "Quantoom Biosciences",
"role": "demerged",
"address": "Rue de la Maitrise 11, 1400 Nivelles",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "0502.742.288",
"name": "UNIVERCELLS",
"role": "recipient",
"address": "Zoning de Jumet, avenue Centrale 52, 6040 Charleroi",
"is_foreign": false,
"legal_form": "Soci\u00E9t\u00E9 anonyme",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"12:59",
"12:8",
"12:60"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": "2024-09-30",
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "La partie \u00E0 scinder comprend l\u0027activit\u00E9 de recherche et d\u00E9veloppement, incluant les moyens op\u00E9rationnels, le personnel, les contrats commerciaux, le fonds de roulement, les subventions, les immobilisations corporelles et incorporelles (notamment brevets, marques, droits d\u0027auteur), ainsi que les donn\u00E9es et bases de donn\u00E9es li\u00E9es \u00E0 cette activit\u00E9. L\u0027ensemble des \u00E9l\u00E9ments non explicitement r\u00E9partis e",
"equity_transferred_eur": null,
"accounting_effective_date": "2024-10-01"
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "Quantoom Biosciences",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "H\u00E9lo\u00EFse Van Houtte",
"org_rep_person_name": null
},
"summary_narrative": "Ce document est un projet d\u0027op\u00E9ration assimil\u00E9e \u00E0 une scission partielle, conform\u00E9ment aux articles 12:59 et 12:8 du Code des Soci\u00E9t\u00E9s et des Associations. La soci\u00E9t\u00E9 Quantoom Biosciences, soci\u00E9t\u00E9 anonyme \u00E0 Nivelles, entend transf\u00E9rer une partie de son patrimoine \u2014 notamment son activit\u00E9 de recherche et d\u00E9veloppement, ses actifs immat\u00E9riels, son personnel et ses contrats \u2014 \u00E0 la soci\u00E9t\u00E9 UNIVERCELLS, \u00E9galement soci\u00E9t\u00E9 anonyme \u00E0 Charleroi. L\u0027op\u00E9ration, qui prend effet juridiquement le 20 d\u00E9cembre 2024, est r\u00E9troactive pour les fins comptables et fiscales \u00E0 partir du 1er octobre 2024. Aucune nouve",
"co_filed_documents": [
"R\u00E9solution \u00E9crite unanime des administrateurs du 29 octobre 2024",
"Rapport du commissaire aux comptes Deloitte R\u00E9viseurs d\u0027Entreprises SRL"
],
"detected_real_type": "demerger_proposal",
"referenced_correction": null,
"should_reroute_to_category": null
}26-02-2024 2 directors appointed, 3 resigning
- Alerion BV, Bestuurder
- Viva Finance SRL, Bestuurder
- Aziz Kabeer, Bestuurder
- Pierre Morgon, Bestuurder
- Jean Prieels, Bestuurder
Technical details
{
"events": [
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Aziz Kabeer",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Pierre Morgon",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Jean Prieels",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Alerion BV",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Viva Finance SRL",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "Quantoom Biosciences"
}
}20-09-2023 Deloitte Réviseur d'Entreprises appointed as auditor
- Deloitte Réviseur d'Entreprises, Auditor
Technical details
{
"events": [
{
"kind": "director_in",
"role": "auditor",
"person": {
"rrn": null,
"name": "Deloitte R\u00E9viseur d\u0027Entreprises",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "QUANTOOM BIOSCIENCES"
}
}12-09-2023 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "Quantoom Biosciences"
},
"legal_form_change": {
"new": "",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}24-11-2022 Capital increase of €13,000,000 to €17,480,481
- €4.480.481 → €17.480.481
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 17480481.0,
"delta_eur": 13000000.0,
"before_eur": 4480481.0,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "Quantoom Biosciences"
}
}20-12-2021 Capital increase of €7,000,000 to €11,160,394
- €4.160.394 → €11.160.394
- Inbreng in geld · Apport en numéraire
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 11160394.0,
"delta_eur": 7000000.0,
"before_eur": 4160394.0,
"contribution_type": "geld"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "Quantoom Biosciences"
}
}24-08-2021 ANTROBUS appointed as director
- ANTROBUS, Bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "ANTROBUS",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "QUANTOOM BIOSCIENCES"
}
}28-05-2021 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "Quantoom Biosciences",
"old": "UNIVERCELLS VACCINES",
"changed": true
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "UNIVERCELLS VACCINES"
},
"legal_form_change": {
"new": "Soci\u00E9t\u00E9 anonyme",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}24-03-2021 Jean-Paul Prieels appointed as board member
- Jean-Paul Prieels, Board member
Technical details
{
"events": [
{
"kind": "director_in",
"role": "board member",
"person": {
"rrn": null,
"name": "Jean-Paul Prieels",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "UNIVERCELLS VACCINES"
}
}04-03-2021 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"name_change": {
"new": "",
"old": "",
"changed": false
},
"seat_change": {
"changed": false
},
"object_change": {
"changed": false
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "UNIVERCELLS VACCINES"
},
"legal_form_change": {
"new": "",
"old": "Soci\u00E9t\u00E9 anonyme",
"changed": false
}
}04-09-2020 3 directors appointed, 1 resigning
- Kabeer Aziz, Bestuurder
- Pierre Morgon, Bestuurder
- José Castillo, Gedelegeerd bestuurder
- Hugues Bultot, Gedelegeerd bestuurder
Technical details
{
"events": [
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Kabeer Aziz",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur",
"person": {
"rrn": null,
"name": "Pierre Morgon",
"address": null,
"birth_date": null
}
},
{
"kind": "director_out",
"role": "administrateur d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Hugues Bultot",
"address": null,
"birth_date": null
}
},
{
"kind": "director_in",
"role": "administrateur d\u00E9l\u00E9gu\u00E9",
"person": {
"rrn": null,
"name": "Jos\u00E9 Castillo",
"address": null,
"birth_date": null
}
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "Univercells Vaccines"
}
}18-06-2020 Capital increase of €7,189,631 to €7,251,131
- €61.500 → €7.251.131
- Inbreng in natura · Apport en nature
Technical details
{
"events": [
{
"kind": "capital_increase",
"after_eur": 7251131,
"delta_eur": 7189631,
"before_eur": 61500,
"contribution_type": "natura"
}
],
"schema": "v3.2",
"act_meta": {
"extractor": "qwen3-30b-a3b"
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "UNIVERCELLS VACCINES"
}
}24-03-2020 Publication in the Belgian Official Gazette, Miscellaneous
Technical details
{
"stage": "proposal",
"notary": {
"name": "Sixtine Borres",
"firm_city": null,
"firm_name": null,
"office_city": "Nivelles",
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2020-03-24",
"filing_date": "2020-03-12",
"act_kind_objet": "DEPOT D\u0027UN PROJET COMMUN D\u0027APPORT D\u0027UNE BRANCHE D\u0027ACTIVITE"
},
"decision": {
"body": "raad_van_bestuur",
"act_date": "2020-03-12",
"unanimous": null
},
"conversion": null,
"detected_kind": "branch_contribution",
"report_waiver": null,
"restructuring": {
"parties": [
{
"kbo": "0502.742.288",
"name": "UNIVERCELLS",
"role": "contributor",
"address": "6041 Charleroi, Rue Auguste Piccard 48",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": "BE"
},
{
"kbo": "0744.643.858",
"name": "UNIVERCELLS VACCINES",
"role": "recipient",
"address": "1400 Nivelles, Rue de la Ma\u00EEtrise 11",
"is_foreign": false,
"legal_form": "SA",
"is_new_company": false,
"jurisdiction_country": "BE"
}
],
"exchange_ratio": null,
"legal_articles": [
"12:93"
],
"is_cross_border": false,
"is_silent_merger": false,
"balance_basis_date": null,
"exchange_ratio_text": null,
"new_shares_issued_n": 0,
"real_estate_included": false,
"patrimony_description": "La branche d\u0027activit\u00E9 \u0027Vaccins\u0027 est transf\u00E9r\u00E9e de la soci\u00E9t\u00E9 UNIVERCELLS \u00E0 la soci\u00E9t\u00E9 UNIVERCELLS VACCINES. Le transfert concerne l\u0027ensemble des actifs, droits et obligations li\u00E9s \u00E0 cette activit\u00E9.",
"equity_transferred_eur": null,
"accounting_effective_date": null
},
"subject_company": {
"kbo": "0744.643.858",
"name_full": "UNIVERCELLS VACCINES",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "person",
"org_kbo": null,
"org_name": null,
"person_name": "Sixtine Borres",
"org_rep_person_name": null
},
"summary_narrative": "Le conseil d\u0027administration de la soci\u00E9t\u00E9 anonyme UNIVERCELLS, dont le si\u00E8ge social est \u00E0 Charleroi, a d\u00E9cid\u00E9, le 12 mars 2020, de transf\u00E9rer sa branche d\u0027activit\u00E9 \u0027Vaccins\u0027 \u00E0 la soci\u00E9t\u00E9 anonyme UNIVERCELLS VACCINES, dont le si\u00E8ge social est \u00E0 Nivelles. Ce projet d\u0027apport de branche d\u0027activit\u00E9 est soumis \u00E0 d\u00E9p\u00F4t et publication conform\u00E9ment \u00E0 l\u0027article 12:93 du Code des soci\u00E9t\u00E9s et des associations.",
"co_filed_documents": [],
"detected_real_type": "branch_contribution",
"referenced_correction": null,
"should_reroute_to_category": null
}04-03-2020 Incorporation of a new SA
Technical details
{
"notary": {
"name": "G\u00E9rard INDEKEU",
"firm_city": null,
"firm_name": "G\u00E9rard INDEKEU - Dimitri CLEENEWERCK de CRAYENCOUR",
"office_city": "Bruxelles",
"is_associated": true
},
"act_meta": {
"language": "fr",
"pub_date": "2020-03-04",
"filing_date": "2020-03-02",
"act_kind_objet": "Objet de l\u0027acte:",
"is_private_deed": false
},
"decision": {
"body": "notarieel_alleen",
"act_date": "2020-02-28",
"unanimous": true
},
"founders": [
{
"org": {
"kbo": "0502.742.288",
"name": "UNIVERCELLS",
"address": "6041 Charleroi, Rue Auguste Piccard 48",
"country": "BE",
"legal_form": "SA",
"foreign_register_name": null,
"foreign_register_number": null
},
"kind": "rechtspersoon",
"person": null,
"share_class": null,
"partner_role": "null",
"contribution_type": "geld",
"amount_paid_in_eur": 61500.0,
"is_subscriber_only": false,
"n_shares_subscribed": 61500,
"amount_subscribed_eur": 61500.0,
"is_anonymous_silent_partner": false
}
],
"voorwerp": {
"full_text": "La soci\u00E9t\u00E9 a pour objet, en Belgique et \u00E0 l\u0027\u00E9tranger, soit directement, soit comme interm\u00E9diaire, tant pour son compte propre que pour le compte de tiers, sauf disposition contraire, ce qui est pr\u00E9vu ci-apr\u00E8s : Favoriser le d\u00E9veloppement de la recherche m\u00E9dicale et biom\u00E9dicale au sens large en vue d\u2019\u00E9laborer et concevoir des produits de toute nature incluant des m\u00E9dicaments ou des techniques m\u00E9dicales, en vue de favoriser tous services, savoir faires ou syst\u00E8mes techniques, sociologiques, philosophiques, psychologiques pouvant contribuer, de mani\u00E8re innovante, \u00E0 la sant\u00E9 et/ou au bien-\u00EAtre de l\u2019homme dans le respect de l\u2019environnement. L\u2019utilisation, la recherche, le d\u00E9veloppement en ce compris l\u2019organisation de tests cliniques, l\u2019exploitation, la transformation, le conditionnement, la fabrication, la promotion, l\u2019achat et la commercialisation sous toutes ses formes de tous produits chimiques ou biologiques, de tous s\u00E9rums, vaccins, toxines, biosimilaires et de tous produits, sous-produits ou d\u00E9riv\u00E9s d\u2019origine animale, v\u00E9g\u00E9tale, microbienne, pouvant servir sous une forme quelconque au diagnostic, \u00E0 la prophylaxie et \u00E0 la th\u00E9rapeutique des maladies humaines ou animales. La recherche et le d\u00E9veloppement, la promotion, l\u2019achat et la vente de tous produits pharmaceutiques, th\u00E9rapeutiques, cosm\u00E9tiques, di\u00E9t\u00E9tiques, \u00E0 usage humain, v\u00E9g\u00E9tal, animal, biologiques, produits chimiques, de tous mat\u00E9riels et instruments m\u00E9dicaux et chirurgicaux, et de mani\u00E8re g\u00E9n\u00E9rale, tous op\u00E9rations industrielles, commerciales, financi\u00E8res ou civiles se rapportant directement ou indirectement aux activit\u00E9s dans le domaine de l\u2019industrie biopharmaceutique. La soci\u00E9t\u00E9 peut r\u00E9aliser tous travaux et tout acte juridique qui sont de nature \u00E0 stimuler directement la r\u00E9alisation de son objet et notamment tout acte mobilier ou immobilier par rapport aux locaux m\u00E9dicaux, l\u2019achat et la vente du mat\u00E9riel m\u00E9dical et non-m\u00E9dical, le recrutement du personnel administratif ou soignant, en service dans la soci\u00E9t\u00E9. Elle ne peut cependant pas faire des actes qui sont contradictoires aux r\u00E8gles de la d\u00E9ontologie m\u00E9dicale. Elle peut constituer, d\u00E9velopper et g\u00E9rer un patrimoine mobilier et faire toutes op\u00E9rations mobili\u00E8res quelconques y compris celles se rapportant \u00E0 tous droits mobiliers comme l\u0027acquisition par voie d\u0027inscription ou de cession et la gestion d\u0027actions, de parts sociales, d\u0027obligations convertibles ou non, de pr\u00EAts de consommation, de pr\u00EAts ordinaires, de bons de caisse ou autres valeurs mobili\u00E8res, de quelque forme que ce soit, tant de personnes morales que d\u0027entreprises, belges ou \u00E9trang\u00E8res, existantes ou encore \u00E0 constituer. La soci\u00E9t\u00E9 pourra exercer tout mandat g\u00E9n\u00E9ralement quelconque ainsi que toute fonction autoris\u00E9e dans toute personne morale belge ou \u00E9trang\u00E8re en ce compris la fonction d\u2019administrateur, de d\u00E9l\u00E9gu\u00E9 \u00E0 la gestion journali\u00E8re, de g\u00E9rant et de liquidateur. Ce mandat pourra \u00EAtre r\u00E9mun\u00E9r\u00E9 ou gratuit. La soci\u00E9t\u00E9 peut, par voie d\u0027apport en esp\u00E8ces ou en nature, de fusion, de souscription, de participation, d\u0027intervention financi\u00E8re ou autrement, prendre des participations dans d\u0027autres soci\u00E9t\u00E9s ou entreprises existantes ou \u00E0 cr\u00E9er, que ce soit en Belgique ou \u00E0 l\u0027\u00E9tranger, dont l\u0027objet serait semblable ou analogue au sien ou de nature \u00E0 favoriser son objet. Elle peut \u00E9galement consentir tous pr\u00EAts ou garantir tous pr\u00EAts consentis par des tiers, \u00E9tant entendu que la soci\u00E9t\u00E9 n\u0027effectuera aucune activit\u00E9 dont l\u2019exercice serait soumis \u00E0 des dispositions l\u00E9gales ou r\u00E9glementaires applicables aux \u00E9tablissements de cr\u00E9dits et/ou financiers. Elle peut faire toutes op\u00E9rations se rapportant directement ou indirectement au management en g\u00E9n\u00E9ral, et plus pr\u00E9cis\u00E9ment, sans que cette \u00E9num\u00E9ration ne soit limitative : la cr\u00E9ation de soci\u00E9t\u00E9s holding ou d\u0027exploitation, toutes activit\u00E9s d\u0027\u00E9tudes et de conseils, toutes prestations de services, tous travaux d\u0027administration, de gestion, tant aupr\u00E8s des entreprises que des particuliers. Elle peut octroyer des conseils et assister en toutes mati\u00E8res \u00E0 des entreprises et \u00E0 l\u2019administration et la gestion d\u2019entreprises. Elle peut faire toutes op\u00E9rations commerciales, industrielles et financi\u00E8res, immobili\u00E8res et mobili\u00E8res, se rapportant directement ou indirectement \u00E0 son objet ou susceptibles de favoriser son d\u00E9veloppement, \u00E0 l\u0027exception des op\u00E9rations sur valeurs mobili\u00E8res et immobili\u00E8res r\u00E9serv\u00E9es par la loi aux banques et aux soci\u00E9t\u00E9s de bourse. Elle peut constituer, d\u00E9velopper, promouvoir et g\u00E9rer un patrimoine immobilier, et r\u00E9aliser toute op\u00E9ration immobili\u00E8re et fonci\u00E8re quelconque, y compris celles se rapportant \u00E0 tous droits r\u00E9els immobiliers comme, entre autres, l\u0027emphyt\u00E9ose, la superficie ou encore le leasing immobilier, le tout dans son acceptation la plus large et notamment : l\u0027acquisition, l\u0027ali\u00E9nation, l\u0027acte de grever, l\u0027\u00E9change, la r\u00E9novation, la transformation, l\u0027am\u00E9nagement, l\u0027entretien, le lotissement, la prospection, l\u0027exploitation, la pr\u00E9paration pour construire, la locatio",
"is_lucrative": true,
"short_summary": "D\u00E9veloppement de la recherche m\u00E9dicale et biom\u00E9dicale, notamment dans les domaines des m\u00E9dicaments, vaccins, produits biologiques, mat\u00E9riel m\u00E9dical et activit\u00E9s connexes, tant en Belgique qu\u2019\u00E0 l\u2019\u00E9tranger."
},
"governance": {
"organ_kind": "raad_van_bestuur",
"n_directors_max": 0,
"n_directors_min": 2,
"representation_clause": "deux administrateurs agissant conjointement ou un administrateur d\u00E9l\u00E9gu\u00E9 agissant seul",
"co_signature_threshold_eur": null
},
"fiscal_year": {
"end_mm_dd": "12-31",
"start_mm_dd": "01-01",
"first_exercise_end_date": "2020-12-31",
"is_prolonged_first_exercise": false
},
"agm_schedule": {
"time": "19:00",
"month": 6,
"rule_text": "troisi\u00E8me jeudi du mois de juin"
},
"founding_event": {
"n_shares_total": 61500,
"n_share_classes": 1,
"bank_attestation": null,
"amount_paid_in_eur": 61500.0,
"incorporation_date": "2020-02-28",
"amount_subscribed_eur": 61500.0,
"art_5_8_no_payment_due": false,
"pre_incorporation_activity_from_date": null
},
"subject_company": {
"kbo": "0744.643.858",
"email": null,
"region": "waals_gewest",
"website": null,
"name_full": "UNIVERCELLS VACCINES",
"legal_form": "SA",
"name_abbreviated": null,
"zetel_address_raw": "1400 Nivelles, Rue de la Ma\u00EEtrise 11",
"equity_account_type": "unavailable",
"_kbo_filled_from_list": true
},
"initial_directors": [
{
"kind": "natural_person",
"person": {
"name": "Hugues BULTOT",
"address": "1150 Woluwe-Saint-Pierre, Avenue de l\u0027Horizon 24"
},
"via_org": null,
"role_sub": "administrateur",
"mandate_until": {
"kind": "until_agm_year",
"value": 2026
},
"rep_person_name": null,
"additional_roles": [
"administrateur-d\u00E9l\u00E9gu\u00E9"
],
"bestuursverbod_checked": false,
"bestuursverbod_check_date": null,
"rep_prior_publication_ref": null
},
{
"kind": "natural_person",
"person": {
"name": "Jos\u00E9 CASTILLO",
"address": "1000 Bruxelles, Rue de la Buanderie 18 bo\u00EEte b3.1"
},
"via_org": null,
"role_sub": "administrateur",
"mandate_until": {
"kind": "until_agm_year",
"value": 2026
},
"rep_person_name": null,
"additional_roles": [
"pr\u00E9sident du conseil d\u0027administration"
],
"bestuursverbod_checked": false,
"bestuursverbod_check_date": null,
"rep_prior_publication_ref": null
}
],
"co_filed_documents": [
"expedition",
"statuten",
"volmacht"
],
"post_incorporation_mandates": [
{
"kind": "volmacht_kbo",
"holder_org_kbo": null,
"holder_org_name": "PwC Legal",
"with_substitution": true,
"holder_person_name": null
}
]
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | Quantoom Biosciences |